drugset / Trial / NCT02867397
Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The goal of the current study was to investigate the safety and determine the maximum tolerated dose (MTD) of S-1 in combination with oxaliplatin and epirubicin in patients with advanced or metastatic solid tumors.
Timeline
- Start
- 2012-01
- Primary completion
- 2015-08
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | S-1 | Small molecule | — | Oral |
| Background | Epirubicin | Small molecule | — | — |
| Background | Oxaliplatin | Small molecule | — | — |
Indications
No indication recorded.